Financial Highlights 2017
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Financial Highlights
| Amounts in millions of EUR, unless otherwise indicated |
2017 | 2016 | Change |
|---|---|---|---|
| Net sales | 18,056 | 15,850 | +14% |
| by region | |||
| Europe | 32% | 32% | |
| Americas | 45% | 41% | |
| Asia, Australia, Africa | 23% | 27% | |
| by business | |||
| Human Pharmaceuticals | 70% | 76% | |
| Animal Health | 22% | 9% | |
| Biopharmaceuticals | 4% | 4% | |
| Other sales | 0% | 0% | |
| Discontinued Operations | 4% | 11% | |
| Research and development expenses | 3,078 | 3,112 | -1% |
| Personnel expenses | 4,934 | 4,570 | +8% |
| Average number of employees | 49,610 | 45,692 | +9% |
| Operating income | 3,487 | 2,872 | +21% |
| Operating income as % of net sales | 19,3% | 18.1% | |
| Group profit/loss | -223 | 1,853 | -112% |
| as % of net sales | -1,2% | 11.7% | |
| Group equity | 10,657 | 11,327 | -6% |
| Return on Group equity | -2% | 19.3% | |
| Investments in tangible assets | 872 | 645 | +35% |
| Depreciation of tangible assets | 521 | 516 | +1% |